#South Korea #Seoul #American Heart Association #Sky Labs #hypertension research

Sky Labs Supports Hypertension Research Award

On March 12, 2026, Sky Labs publicly unveiled its commitment to the Established Investigator Award for Clinical Hypertension, an initiative launched by the American Heart Association (AHA). This announcement follows a memorandum of understanding signed with the AHA in September 2025, highlighting Sky Labs' dedication to advancing research in hypertension on a global scale.

Funding for Breakthrough Research

Sky Labs will allocate a total of approximately $90,000 to support this award, which is set to recognize three outstanding researchers who have made significant contributions to the field of hypertension from 2026 to 2028. The funding will cover the annual fees for selected researchers as well as all operational costs associated with running the award program, reinforcing the company’s commitment to impactful scientific research.

In order to qualify for this prestigious award, researchers must be members of the AHA's Scientific Council on Hypertension. This requirement ensures that recipients are actively engaged in the latest advancements and discussions within the field, thereby fostering a community of innovation and collaboration.

Commitment from Sky Labs

Jack Byunghwan Lee, CEO of Sky Labs, expressed the company’s pride in supporting the AHA, stating, "We are deeply honored to support the American Heart Association and contribute to the advancement of global hypertension research. We will also enhance our clinical research efforts to validate the effectiveness of blood pressure management solutions, while continuing our R&D endeavors to support these initiatives." Lee’s comments underscore Sky Labs' dual focus on both funding external research and advancing its proprietary technologies.

Innovations in Hypertension Management

Sky Labs, founded in September 2015, is a health technology company that leverages artificial intelligence to develop innovative chronic disease management solutions. Their flagship product, CART, is the world’s first medical-grade portable blood pressure monitor designed as a ring, allowing users to continuously measure their blood pressure in a non-intrusive manner. This innovative approach represents a significant leap in personal health technology.

Since the initial development of CART in 2020, aimed at monitoring atrial fibrillation utilizing optical signals, Sky Labs has continuously expanded its technological capabilities. In 2023, the company received medical device approval for its CART BP pro, intended for 24-hour blood pressure measurement, and this product has been prescribed in hospitals across South Korea.

In September 2025, Sky Labs further expanded its offerings by launching CART BP, a consumer-friendly portable blood pressure monitor available through its official online store and various other e-commerce platforms. This product aims to make hypertension management more accessible, promoting healthier lifestyles and better health outcomes for a broader audience.

A Bright Future for Hypertension Research

By supporting the Established Investigator Award, Sky Labs not only invests in research that could transform hypertension management but also amplifies its commitment to public health initiatives. The partnership with the AHA represents a pivotal moment in both organizations' missions to tackle hypertension — a major public health challenge worldwide.

In conclusion, the collaboration between Sky Labs and the American Heart Association opens up new avenues for research and innovation in hypertension treatment. As the world faces increasing rates of this silent threat, initiatives such as the Established Investigator Award stand to play a crucial role in advancing our understanding and management of high blood pressure.

For more information about Sky Labs and its initiatives, visit Sky Labs Official Site.